MaxCyte (MXCT) Earnings Analysis

MaxCyte (MXCT) next reports earnings on 2026-08-12, consensus EPS -0.12 USD. Last quarter (2026-03-24) it beat with EPS -0.06 USD vs -0.08 USD est (+25%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -3.05.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MXCT next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-0.12 USD
Revenue estimate0.01B

MXCT earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-24-0.06 USD-0.08 USD+25%Beat
2025-11-12-0.12 USD-0.11 USD-9.1%Miss
2025-03-11-0.1 USD-0.12 USD+16.7%Beat

Beat rate: 2/3 (67%) over reported quarters with consensus data.

MXCT valuation and analyst view

Trailing P/E-3.05
Trailing EPS-0.36603 USD
Price / book0.73
Dividend yield0.00%
Market cap0.13B
Analyst consensusBuy (4 buy / 2 hold / 0 sell)

Related research pages

Frequently asked questions

When is MaxCyte (MXCT)'s next earnings date?

MaxCyte is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.12 USD and revenue estimate of 0.01B.

Did MXCT beat earnings last quarter?

In its 2026-03-24 report, MXCT posted EPS of -0.06 USD versus a -0.08 USD estimate — a beat of 25%.

What is MXCT's earnings track record?

Over the last 3 reported quarters with consensus data, MXCT beat estimates 2 times (67%).

What is MXCT's current P/E ratio and EPS?

MXCT trades at a trailing P/E of -3.05 on trailing EPS of -0.36602543303660656 USD.

What do analysts rate MXCT?

Analyst consensus is "Buy" across 6 ratings (0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell).